Results 211 to 220 of about 32,854 (248)
Some of the next articles are maybe not open access.
Nanotechnology in ocular drug delivery
Drug Discovery Today, 2008Despite numerous scientific efforts, efficient ocular drug delivery remains a challenge for pharmaceutical scientists. Most ocular diseases are treated by topical drug application in the form of solutions, suspensions and ointment. These conventional dosage forms suffer from the problems of poor ocular bioavailability, because of various anatomical and
Sanjeeb K, Sahoo +2 more
openaire +2 more sources
Ocular Drug Delivery: Nanomedicine Applications
Nanomedicine, 2007Nanocarriers, such as nanoparticles, liposomes and dendrimers, are used to enhance ocular drug delivery. Easily administered as eye drops, these systems provide a prolonged residence time at the ocular surface after instillation, thus avoiding the clearance mechanisms of the eye.
Vandervoort, Jo, Ludwig, Annick
openaire +3 more sources
Recent advances in ocular drug delivery
Drug Development and Industrial Pharmacy, 2012Amongst the various routes of drug delivery, the field of ocular drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. Recent research has focused on the characteristic advantages and limitations of the various drug delivery systems, and further research will be required before the ideal system can ...
Djamila, Achouri +3 more
openaire +2 more sources
The Role of Iontophoresis in Ocular Drug Delivery
Journal of Ocular Pharmacology and Therapeutics, 1994Iontophoresis has been utilized in the field of ophthalmology for many years. Present application of this technique has diminished considerably and few clinicians are currently familiar with its use. This review aims to educate the reader regarding the essential features of this procedure and to discuss the past and future role of iontophoresis in ...
D, Sarraf, D A, Lee
openaire +2 more sources
Designing dendrimers for ocular drug delivery
European Journal of Medicinal Chemistry, 2010New series of phosphorus-containing dendrimers, having one quaternary ammonium salt as core and carboxylic acid terminal groups have been synthesized from generation 0 (3 carboxylic acid terminal groups) to generation 2 (12 carboxylic acid terminal groups). These dendrimers react with the neutral form of carteolol (an ocular anti-hypertensive drug used
Grégory, Spataro +7 more
openaire +2 more sources
Ocular drug delivery in veterinary medicine
Advanced Drug Delivery Reviews, 1997This paper provides a comprehensive overview of the various approaches currently used in the development of ocular drug delivery systems for the treatment of ocular diseases in animals. It is obvious from the literature that most of the products that are currently available are derived from human medicine without consideration given to the differences ...
Baeyens, Vincent +5 more
openaire +3 more sources
Effect of menthol on ocular drug delivery
Graefe's Archive for Clinical and Experimental Ophthalmology, 2011To assess how safe and effective it is to use menthol as a permeability enhancer in ophthalmic drug delivery systems.In this study, the effect of menthol on permeability of dexamethasone disodium phosphate in the cornea and sclera was investigated in vitro.
Xiaolin, Xu +6 more
openaire +2 more sources
Redefining ocular drug delivery
The Ocular Surface, 2022Allisa J. Song +2 more
openaire +2 more sources
Cationic Vectors in Ocular Drug Delivery
Journal of Drug Targeting, 2004Despite extensive research in the field, the major problem in the ocular drug delivery domain still is rapid precorneal drug loss and poor corneal permeability. One of the approaches recently developed is the drug incorporation into cationic submicronic vectors which exploit the negative charges present at the corneal surface for increased residence ...
Laura, Rabinovich-Guilatt +3 more
openaire +2 more sources
Drug delivery from ocular implants
Expert Opinion on Drug Delivery, 2006Developing an intraocular drug delivery system (DDS) is urgently needed because most vitreoretinal diseases are refractory to conventional pharmacological approaches; eye drops and systemically administered drugs cannot deliver therapeutic drug concentrations into vitreoretinal tissue. Intraocular DDSs address this problem.
Tsutomu, Yasukawa +4 more
openaire +2 more sources